Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
After starting 2024 strong, Eli Lilly (NYSE: LLY) did not perform well in the second half of last year. Its financial results ...
2h
The growing interest in Mounjaro shows an increasing awareness of metabolic health, which is a positive trend. However, ...
Eli Lilly's Mounjaro, a new diabetes and weight loss drug, is making waves in India. Approved by the drug regulator, this ...
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback